Decrease in PSE scores in patients with hepatic encephalopathy on low dose rifaximin


eMediNexus    24 July 2018

A recent study published in PJMHS evaluated the mean decrease in porto-systemic encephalopathy (PSE) score in patients with hepatic encephalopathy treated with rifaximin. In all, 300 patients (Males 164 (54.7%); mean age of patients 50.07 + 11.59 years) were included in the study. There were 12.7% patients with Child’s class A, 42% with child’s class B while 45.3% with Child’s class C. Mean PSE score (Conn’s score) before treatment initiation was 3.17 + 0.721 while after completion of treatment, the score was 1.79 + 0.879. The improvement in PSE score was statistically significant among males and females, across various age groups and in patients with various classes of Child Pugh score. It was thus concluded that rifaximin is an effective treatment option in patients with cirrhosis of liver having hepatic encephalopathy and that the drug yields significant improvement in PSE score (Conn s’ score) among patients with hepatic encephalopathy.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.